Support for a Well Established Use dossier in the European Union

Case studies - 18 September 2020

Support for a Well Established Use dossier in the European Union

BlueReg (BR) was involved in the elaboration of a well-established use (WEU) dossier for an orphan drug in a life threatening and debilitating condition for the European Medicines Agency (EMA). BR initiated a systematic review of the literature on clinical aspects to support the WEU justification and updated it in line with regulatory requirements. BR also structured the non-clinical and clinical overview sections of this Common Technical Document (CTD). A regulatory risk / mitigation assessment was conducted for each WEU eligibility criteria in view of an EMA pre submission meeting.

Did you like this article? Share on social networks:


    By sending this form, I agree that my personal data will be saved and processed according to data protection regulations and will be used only for commercial and marketing purposes only.

    Learn more


    BlueReg undertakes to comply with the regulations in force applicable to the processing of personal data and, in particular, Regulation (EU) 2016/679 of the European Parliament and of the Council of 27 April 2016 applicable as from 25 May 2018 (hereinafter, "the General Data Protection Regulations" or GPDR) and the national laws resulting therefrom.
    Any inquiries, correction or declaration of event related to personal data processed should be sent to: GDPR data request

    Thank you for your reply

    The file will be sent to you by email.

    Download